Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin
- 9 June 2018
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 22 (1) , 138-146
Abstract
We investigated early tumor shrinkage (ETS) and depth of response (DpR) using data from the G-SOX study comparing S-1 plus oxaliplatin with S-1 plus cisplatin as the first-line treatment for advanced gastric cancer (AGC).Keywords
This publication has 18 references indexed in Scilit:
- Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancerGastric Cancer, 2017
- Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumabOncotarget, 2017
- Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)International Journal of Cancer, 2017
- Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05)Targeted Oncology, 2016
- Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)European Journal of Cancer, 2015
- Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestAnnals of Oncology, 2015
- Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2013
- Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan‐based randomized first‐line trialCancer Science, 2013
- Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trialActa Oncologica, 2012
- The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapyAnnals of Oncology, 2011